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A report on the Keystone Symposium ‘Cancer Genomics
and Epigenomics’, Taos, USA, 19-24 February 2008.
Unlike heart disease, the overall mortality rate for cancer
has not significantly improved over the past 50 years,
indicating an unmet need for better cancer treatments, in
particular for targeted therapies that are more effective and
less toxic than traditional cytotoxic chemotherapy.
Development of such therapies requires a detailed
understanding of cancer genomes, including the effects of
epigenomic modifications. A recent Keystone Meeting on
cancer genomics and epigenomics addressed this knowledge
gap, and some of the highlights are presented here.
G Ge en no om mi ic c   l le es si io on ns s   i in n   c ca an nc ce er r   c ce el ll ls s
Complete characterization of lesions in the genomes of tumor
cells is fast becoming a reality. The extent to which technology
drives discovery was especially apparent in the talks on cancer
genome analysis. Next-generation single-molecule sequencing
technologies, such as those developed by the companies
Solexa and 454, have already been successfully applied to
answer questions about both genomic and epigenomic
organization. In addition, many participants reported the
application of more traditional approaches to characterization
of the three main types of genomic lesions in cancer:
translocations, copy-number changes and point mutations.
High-throughput discovery of translocations has been ex-
plored by both array-based and sequencing-based approaches,
but has proved to be difficult. Aleks Milosavljevic (Baylor
College of Medicine, Houston, USA) has used a combination
of traditional Sanger sequencing and 454 single-molecule
pyrosequencing to identify translocations in bacterial arti-
ficial chromosome (BAC) clones created from the MCF-7
breast cancer cell line. His group successfully identified 157
PCR-confirmed breakpoint junctions, 10 of which were
located in introns so that the reading frame was preserved.
Several of these in-frame translocations were also confirmed
at the transcript level. It is anticipated that developments in
single-molecule sequencing technology will further facilitate
this approach.
In contrast to translocation discovery, global assessment of
copy-number changes by comparative genomic hybridization
(CGH) and its more recent variants is well established. How-
ever, increased resolution of segment breakpoints can be theo-
retically achieved using single-molecule sequencing techno-
logies, and Matthew Meyerson (Dana-Farber Cancer Institute,
Boston, USA) presented preliminary data on the development
and application of Solexa sequencing for use in higher-
resolution digital karyotyping of copy-number alterations.
Copy-number data obtained by these techniques can be used
to subclassify tumor samples by patterns of amplification
and deletion. These data can also be computationally
analyzed to identify putative driver genes under positive
selection in recurring copy-number lesions, and many groups
are actively working on such algorithms. Michael Wigler
(Cold Spring Harbor Laboratory, USA) presented a metric in
which each deletion/amplification event is assumed to have
a driver, the assigned weight for which is inversely propor-
tional to the number of genes in the DNA segment affected.
Meyerson presented the technique of ‘genomic identification
of significant targets in cancer’ (GISTIC), which assigns a
score to each amplified or deleted segment on the basis of its
frequency and the number of copies deleted or amplified. He
reported the application of GISTIC to lung adenocarcinoma
copy-number data from the Tumor Sequencing Project, which
identified a novel recurrently amplified lineage-specific onco-
genic transcription factor in lung adenocarcinoma, NKX2-1.
Donna Albertson (University of California, San Francisco,
USA) and her colleagues have combined copy-number and
expression information to identify the gene GLI2 as the
putative driver of a narrow amplicon in oral squamous cell
carcinomas. She also reported the experimental investigation
of the functional consequences of GLI2 overexpression by co-
culture of HaCat keratinocytes ectopically expressing GLI2
with fibroblasts in three-dimensional organotypic cultures.Single-molecule sequencing is also poised to revolutionize
mutation discovery in tumor DNA. As the cost decreases, it
should soon be possible to routinely sequence all expressed
genes in many samples, with the ultimate goal of identifying
novel therapeutic targets. I presented data on therapeutic
targets that have been identified by old-fashioned Sanger
sequencing, including the mutations in the kinase domain of
the epidermal growth factor receptor gene (EGFR) in lung
adenocarcinoma, which predict response to EGFR-targeted
therapeutics such as erlotinib. More recently, we have
identified EGFR extracellular domain mutations in glioblas-
toma, as well as mutations in the fibroblast growth factor
receptor 2 gene (FGFR2) that confer sensitivity of endo-
metrial carcinoma cell lines to FGFR inhibitors.
E Ep pi ig ge en no om mi ic c   c ch ha an ng ge es s   i in n   c ca an nc ce er r
Talks on cancer epigenomics substantially outnumbered those
on the genome, indicating the growing interest in this exci-
ting field. Many candidate driver genes have been identified
by examination of differentially methylated sequences in
tumor cells using methylation-sensitive restriction enzymes.
For example, Kornelia Polyak (Dana-Farber Cancer Insti-
tute, Boston, USA) has examined genes that are differen-
tially methylated in breast epithelium bipotential progenitor
cells compared with a more differentiated luminal epithelial
cell population. She found that the transcription factor FOXC1
is hypomethylated in the progenitor population in both normal
and neoplastic breast tissue, and that ectopic expression of
FOXC1 in differentiated mammary epithelial cells induced a
progenitor-like migratory and invasive phenotype.
Tomas Ekstrom (Karolinska Institute, Stockholm, Sweden)
described a method for detecting the global extent of cyto-
sine methylation - the ‘luminometric methylation assay’
(LUMA). His group has used this assay to show that
infection with human cytomegalovirus (CMV), which is asso-
ciated with several cancers but is not known to be sufficient
for tumor initiation, results in a global reduction of DNA
methylation correlated with nuclear exclusion of DNA
methyltransferases, raising the possibility of an epigenetic
contribution of CMV to cancer.
Single-molecule sequencing has also propelled the study of
the cancer epigenome forward. Stephan Beck (University
College London, UK) presented data coupling precipitation
of methylated DNA sequences by antibody specific for 5-
methyl cytosine (meDIP) with Solexa sequencing, showing
that this provides increased resolution over the more
conventional array-based identification of meDIP-precipi-
tated sequences (meDIP-chip).
Bradley Bernstein (Massachusetts General Hospital, Boston,
USA) has combined Solexa sequencing with chromatin
immunoprecipitation (ChIP-Seq) in a genome-wide study of
the correlation between histone H3 lysine methylation and
transcriptional activity in an effort to better understand the
transition from pluripotent stem cell to lineage-committed
cell. Sheared chromatin from mouse embryonic stem cells
(ES cells), neural progenitor cells (NPCs) and mouse embryo
fibroblasts (MEFs) was precipitated with antibodies to
specific methylation states of histone H3, and the eluted
DNA used to make libraries for Solexa sequencing. The
results showed that CpG-rich promoters in ES cells were
primarily associated with tri-methylated H3 lysine 4
(H3K4me3), a modification associated with transcribed
chromatin, and likely to denote housekeeping genes.
However, a small fraction of CpG-rich promoters in the ES
cells was also precipitated along with tri-methylated H3
lysine 27 (H3K27me3), and these doubly modified promoters
were for the most part not transcriptionally active. Many of
the doubly modified promoters in ES cells had only a single
modification in the lineage-committed NPCs and MEFs; for
example, the promoter of the neural transcription factor
gene  OLIG1 was associated with H3K4 tri-methylation in
NPCs but only H3K27 tri-methylation in MEFs. Bernstein
also showed that retention of H3K27 methylation in
differentiated cells is dependent on expression of the
Polycomb repressive complex protein PRC1.
The special AT-rich binding protein 1 (SATB1) binds base-
unpairing regions (BURs) of genomic DNA to organize
chromatin into loops. It also establishes region-specific
epigenetic status at its target gene loci by recruiting
chromatin-remodeling factors. Terumi Kohwi-Shigematsu
(Lawrence Berkeley National Laboratory, Berkeley, USA)
described the cloning of genomic sequences juxtaposed to
the BUR associated with the MYC locus. She and her
colleagues found that genes encoding known c-Myc binding
partners and other signaling proteins controlling MYC
expression are brought into close proximity to the MYC gene
in the nuclear space. SATB1 is overexpressed in metastatic
breast cancer cell lines and is associated with poor prognosis
in primary breast tumor samples.
S Sc cr re ee en ni in ng g   f fo or r   p po ot te en nt ti ia al l   t th he er ra ap pe eu ut ti ic c   t ta ar rg ge et ts s
One goal of the characterization of genomic and epigenomic
lesions in cancer, in addition to a deeper understanding of
basic cancer biology, is the identification of novel therapeutic
targets. Functional genomics provides an approach to
identifying such targets even in the absence of a compre-
hensive description of the cancer-associated genomic lesions.
A number of excellent talks described RNA interference
screens using small hairpin RNA (shRNA) to reveal tumor
dependencies and genes responsible for drug resistance.
René Bernards (Netherlands Cancer Institute, Amsterdam,
the Netherlands) described an shRNA screen to identify
genes that confer resistance to the antibody trastuzumab
(Herceptin) in BT-474 breast cancer cells when knocked
down. PTEN, a negative regulator of the phosphatidylinositol
3-OH kinase gene PIK3CA, was identified in this screen.
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sufficient to confer resistance to trastuzumab in the SK-BR3
breast cancer cell line. Bernards also reported that breast
cancer patients whose tumors were characterized by either
low levels of PTEN expression or PIK3CA mutations
(mutually exclusive) exhibited a statistically significant
decrease in survival following trastuzumab-based therapy.
Consistent with these results, he reported that inhibitors of
PI3K overcome trastuzamab resistance due to PTEN loss or
PIK3CA mutation in cultured cells.
Owing to these technological advances, we are now poised
for a comprehensive characterization of the cancer genome.
There is no doubt that exponentially increasing volumes of
data will be generated, necessitating development of compu-
tational approaches to make full use of the biologically
relevant information contained within.
http://genomebiology.com/2008/9/5/309 Genome B Bi io ol lo og gy y 2008, Volume 9, Issue 5, Article 309 Greulich 309.3
Genome B Bi io ol lo og gy y   2008, 9 9: :309